Treatment and prevention options, including therapeutics, antiviral drugs and vaccines, are critically needed to mitigate 2019 novel coronavirus infections (COVID-19). With this in mind, the U.S. Department of Health and Human Services will expand an existing partnership with Janssen Research and Development, a component of US-based Johnson and Johnson to advance the development of potential COVID-19 antivirals through early clinical evaluation.
The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), will provide Janssen with technical expertise funding to accelerate the discovery and development process. The funding will support manufacturing, nonclinical studies, phase 1 clinical trial(s), and regulatory requirements of promising antiviral candidates identified through ongoing screening being supported as part of our existing partnership.
The development of safe and effective therapeutics and antiviral drugs for the treatment of emerging infectious diseases, such as the rapidly spreading 2019 novel coronavirus (SARS-CoV-2), is a high priority for the US government and industry. The long standing partnership between BARDA and Janssen allowed for rapid identification of potential antiviral compounds that have activity against SARS-CoV-2 and to move these candidates forward into first-in-human studies.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.
Janssen is creating a future where disease is a thing of the past as the Pharmaceutical Companies of Johnson & Johnson. They work tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. Janssen focuses on areas of medicine where it can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.